Mobile

Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene...

Mise à jour : Il y a 5 ans
Référence : EUCTR2010-021255-81

Multicenter, open-label, randomized study to evaluate inhibition of ovulation during treatment with three transdermal patch formulations containing 0.55 mg ethinylestradiol (EE) and 2.10 mg gestodene (GSD) or 0.35 mg EE and 0.67 mg GSD or 0.275 mg EE and 1.05 mg GSD in healthy young female volunteers over a period of 3 treatment cycles

Femme Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective of this study is to evaluate the inhibition of ovulation in treatment cycles 2 and 3 after dermal application of 3 different patch formulations containing ethinylestradiol (EE) / gestodene (GSD) for 3 treatment cycles

Critère d'inclusion

  • Prevention of pregnancy

Liens